Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
Mangiacavalli
Silvia
S
Pica
Gianmatteo
G
Varettoni
Marzia
M
Lazzarino
Mario
M
Corso
Alessandro
A
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D012008:Recurrence
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine